Physician profile
Mark F Young
NPI 1568466969
$6,838.63
in general payments reported to CMS, 2019-2025
34 companies · $896 in 2025
The $896 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $564 · 2021: $1,032 · 2022: $1,178 · 2023: $1,169 · 2024: $1,107 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,172.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,008.52 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,036.68 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $530.91 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $338.82 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $267.94 | 2019-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $217.95 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $158.40 | 2021-2025 | |
| Celgene Corporation | $134.47 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $125.01 | 2024 | |
| Daiichi Sankyo INC. | $117.04 | 2020-2023 | Injectafer |
| Qol Medical, LLC | $109.63 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $98.84 | 2021-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $95.73 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $89.99 | 2021-2023 | |
| Genzyme Corporation | $80.63 | 2023-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $55.23 | 2025 | Zenpep |
| Olympus America INC. | $52.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.80 | 2022-2025 | Dupixent |
| Enterra Medical, INC. | $32.51 | 2025 | |
| Ardelyx, INC. | $29.14 | 2022 | |
| Romark Laboratories, Lc | $27.73 | 2019-2020 | |
| Ucb, INC. | $27.53 | 2019 | |
| Lilly USA, LLC | $20.68 | 2024 | Omvoh |
| Mallinckrodt Hospital Products INC. | $19.83 | 2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $18.05 | 2022 | |
| Celltrion USA INC. | $16.62 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $16.11 | 2024 | Iqirvo |
| Madrigal Pharmaceuticals | $15.11 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2023 | Cyltezo |
| Capsovision, INC. | $13.46 | 2023 | Capsocam Plus |
| Evoke Pharma, INC. | $12.72 | 2022 | |
| Boston Scientific Corporation | $12.11 | 2020 | |
| Mauna Kea Technologies, INC. | $9.39 | 2024 | |
| Phathom Pharmaceuticals, INC. | $2.31 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.